Early Warning and Classification Model for Acute Non-traumatic Chest Pain

ConditionChest Pain

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorXiao-nan He

About this trial

Acute non-traumatic chest pain is one of the common causes of presentation in emergency patients, but the causes of acute non-traumatic chest pain are complex, the severity of the condition varies greatly, and the specificity of symptoms is not high. Machine learning and intelligent auxiliary models can greatly shorten the time of clinical decision-making, and improve the accuracy of etiological diagnosis in patients with chest pain, reduce the rate of misdiagnosis and missed diagnosis, and provide a clear direction for further treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years

Symptom onset or worsening within 24 hours before presentation, with a chief complaint of acute chest pain meeting the broad definition of chest pain (2021 AHA)

Presentation to the emergency department, with a clinical diagnosis consistent with non-traumatic chest pain

Signed informed consent

Disqualifiers

traumatic chest pain

systemic pain caused by malignant tumors or rheumatic diseases involving the chest

Patients were lost to follow-up

Trial population

The study population included patients admitted to the chest pain center of the pilot hospital from August 2022 to December 2027 with chest pain (including tingling, burning pain, pressure, tightness, heartburn and similar discomfort) as the main manifestations. Screening of patients with chest pain is intended from the following sources: 1. outpatients with chest pain; 2. outpatients with a history of cardiovascular disease; 3. patients from other departments of the hospital referred to the cardiology outpatient clinic due to acute chest pain.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Clinical evaluation, laboratory and cardiac imaging results, medication, surgery, and any hospitalization
Combination product
Examination： Electrocardiogram、 imaging examination、 X-ray, CTA, bedside echocardiography. Laboratory test results of patients, including complete blood count, D-dimer, myocardial injury markers, sST2, MPO, and other indicators. History of cardiovascular and pulmonary vascular drug therapy: Antithrombotic therapy (type, measurement) , Anticoagulation therapy (type, metering), Other drug treatments (type, measurement)

Treatment groups

10,000 Participants

are divided into 2 treatment groups

Group A: No cardiovascular adverse and cerebrovascular events (MACCE) occurred during the 1-month period1 intervention

Group B: Group of major cardiovascular and cerebrovascular adverse events (MACCE) occurring during 1 month1 intervention

Trial outcomes

Primary outcomes

Adverse events

The primary outcome was a composite of adjudicated major adverse cardiovascular and cerebrovascular events (MACCE), which included cardiovascular death, all-cause mortality, nonfatal myocardial infarction, refractory angina, new onset heart failure and stroke.

Time frame

30 days after presenting to the emergency departments(ED)

Other outcomes

Differences in accuracy in diagnosing acute non-traumatic chest pain using machine learning and intelligence-assisted models and existing scoring systems.

Cross-disciplinary testing

Time frame

Week 12

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Xiao-nan He

Lead sponsor

Beijing Anzhen Hospital

Sponsor institution

Source ClinicalTrials.gov

Apply now